КОРОНАВИРУС ИНФЕКЦИЯСИДАН КЕЙИНГИ ҚАЛҚОНСИМОН БЕЗДА ФУНКЦИОНАЛ ЎЗГАРИШЛАР
Abstract
The novel coronavirus, known as severe acute respiratory syndrome coronavirus-2 (SARS-COV-2), is the cause of the global coronavirus 19 (COVID-19) pandemic that began in late 2019. COVID-19 infection can range from very mild to asymptomatic leading to critical illness and death. Along with several organ systems that can be affected by COVID-19 is the thyroid gland. In some patients, COVID-19 infection can trigger a hypersensitive immune response and widespread inflammation, known as a “cytokine storm.” Because the most common causes of thyroid problems are antibodies attacking the thyroid (autoimmune thyroid disease), this activation of the immune system can also cause inflammation and thyroid dysfunction. The thyroid may also be affected indirectly as a result of the overall severity of the infection.
Key words: SARS-CoV-2, COVID-19, thyroid gland, subacute thyroiditis.
Purpose: The purpose of the study was to evaluate thyroid function in all patients admitted to the hospital with confirmed COVID-19 to determine if this infection was associated with abnormal thyroid function.
Materials and methods. The study evaluated 93 consecutive patients admitted with COVID-19 infection to the therapeutic department of the Bukhara Regional General Hospital in 2020. The non-COVID group included 110 consecutive ICU patients with a thyroid function test. available results. Patients with pre-existing thyroid disease were excluded, so data from 78 patients in the COVID-19 group and 85 patients in the control group were analyzed.
Research results. The COVID-19 group was younger and included more men than women compared to the non-COVID control group (mean age 65 vs 73 years; men 69% vs 56%). In the COVID-19 group, 13 of 85 (15%) patients showed hyperthyroidism on thyroid function tests compared to 1 of 78 (1%) in the control group. More men than women had abnormal thyroid function tests (64% vs 36%). In patients with hyperthyroidism, serum TSH levels were low, while serum free T levels were low. T4 levels remained within the normal range and were similar in both groups. Without serum T3 levels were low and similar in both groups.
Conclusions. The results of this study showed that thyroid dysfunction is common in patients with COVID-19, with low TSH most commonly found. While more research is needed, these studies suggest that systemic immune activation-associated COVID-19 can cause thyroid inflammation and lead to hyperthyroidism or thyroiditis.
References
Guo Y, Korteweg C, McNutt MA, Gu J (2008) Патогенетические механизмы тяжелого острого респираторного синдрома. Вирус Res 133: 4–12.
Yaxyayeva Hilola Sharifovna. Thyroid Cancer Diagnostics, Classification, Staging.// Ижтимоий Фанларда Инновация онлайн илмий журнали//2021.—P. 63-69
YH Sharifovna COVID-19 infection and thyroid function //Eurasian Medical Research Periodical// 7, 2022 -- P.167-170
Zhu N, Zhang D, Wang W, Li X, Yang B, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
Вадуганатан М., Вардени О., Мишель Т., МакМюррей Дж.П., Пфеффер М.А., и другие. (2020) Ингибиторы ренин-ангиотензин- альдостероновой системы у пациентов с Covid-19. N Engl J Med 382: 1653–1659.
Лонг Б., Брэди В.Дж., Койфман А., Готтлиб М. (2020) Сердечно-сосудистые осложнения при COVID-19. Am J Emerg Med 38: 1504–1507.
Маттар САМ, Ко С.Дж.К., Рама Чандран С., Чернг БПЗ (2020) Подострый тиреоидит, связанный с COVID-19. Представитель BMJ Case 13: e237336.
Трошина Е.А., Мельниченко Г.А., Сенюшкина Е.С., Мокрышева Н.Г. Адаптация гипоталамо-гипофизарно-тиреоидной и гипоталамо-гипофизарно-надпочечниковой систем к новому инфекционному заболеванию — COVID-19 в условиях развития COVID-19-пневмонии и/или цитокинового шторма. Клиническая и экспериментальная тиреоидология. 2020;16(1):21-27.
Хилола Шарифовна Яхъяева. COVID-19 И ЩИТОВИДНАЯ ЖЕЛЕЗА (ОБЗОР ЛИТЕРАТУРЫ) // ЖУРНАЛ БИОМЕДИЦИНЫ И ПРАКТИКИ// 2021.—P. 294-300
Чжу З., Цай Т., Фань Л., Лу К., Хуа Х, и другие. (2020) Клиническое значение иммуно-воспалительных параметров для оценки степени тяжести коронавирусной болезни 2019 г. Int J Infect Dis 95: 332–339.
